Morgan Stanley Lifts Merck Target, but the $113 Cap Says: Don't Get Excited Yet

Morgan Stanley's upgrade is constructive, not enthusiastic

Morgan Stanley kept Merck at Equal-Weight and raised its target only from $112 to $113. That is the hallmark of a constructive update, not a fresh burst of enthusiasm for the stock.

Why the quarter mattered

Merck gave investors more concrete evidence that the core business is still functioning well. In the first quarter, Keytruda sales rose 12% to $8 billion, above expectations of $7.6 billion. Management also lifted its 2026 outlook to $65.8 billion to $67 billion in revenue and $5.04 to $5.16 in profit per share. For a company still centered on Keytruda, that matters.

Why the rating matters more than the target bump

The ceiling is the point. Even with Guggenheim recently lifting its target to $140, Merck shares were already trading near recent highs. The broader Street view remains constructive, with a Moderate Buy consensus and an average 12-month target around $134.50.

So Morgan Stanley's move looks more like a modest reprice than a paradigm shift. The business may be improving, but the stock already reflects much of that good news.

Merck's operating breadth is showing up in the numbers

The upside case is not about mystery. It is about whether revenue drivers are still contributing.

Keytruda is still the anchor, but it is not the only data point

In the latest quarter, Merck reported total worldwide sales of $16.6 billion, up 5%. Keytruda and Keytruda Q-Lex sales reached $8.4 billion, up 5%, including $463 million from Keytruda Q-Lex. That suggests the transition product is contributing, which matters more than a single quarterly beat.

Winrevair and animal health add useful diversification

Winrevair sales reached $588 million, up 75%, and animal health sales reached $1.8 billion, up 8%. That does not remove Keytruda dependence, but it does weaken the simplest version of the bear case that Merck has no other meaningful growth drivers.

Guidance tightened, which supports the execution story

Merck also narrowed and raised its full-year outlook to $66.3 billion to $67.3 billion in sales and $2.66 to $2.76 in non-GAAP EPS. That is a meaningful signal because tighter, higher guidance usually reflects stronger internal confidence.

That is also why Guggenheim's $140 price target is relevant. The firm kept its Buy rating and updated its model with revised assumptions for intravenous Keytruda loss of exclusivity. The bullish argument is not that Keytruda suddenly gets another full decade of run-rate growth; it is that the exclusivity transition may be slower than pessimists expect.

The main limit is still profit quality

Morgan Stanley previously noted that Q3 was helped by one-timers even as Keytruda and Winrevair missed expectations. Management also flagged an acceleration in operating expense.

That keeps the real scorecard simple: new launches need to keep contributing, and spending cannot outrun revenue long term.

What kind of stock is Merck now?

The practical stance is watchful ownership, not blind chasing. Wall Street still rates the stock a Moderate Buy, with a mean price target of $132.13 and an average target of $134.50. That is supportive, but it is not a buy-at-any-price call.

The shareholder return profile also matters. Merck has maintained dividend payments for 56 consecutive years and expects approximately $3 billion in share repurchases for 2026. That gives the stock a more measured appeal: income, steadier execution, and gradual compounding rather than an obvious rerating.

Recent results also support that view. Merck still has contributions from launches such as Winrevair, alongside continued strength in oncology and animal health.

What supports the bullish case

• A long dividend record and meaningful buybacks can support the stock even if equity upside is gradual.
• Guidance revisions are moving in the right direction, which helps the execution narrative.
• The business is showing more than one commercial contributor, which makes the steady-growth case more believable.

What could limit upside

• An acceleration in operating expense could pressure profit quality if growth does not keep pace.
• If launch contributions fade, Merck starts to look too narrow again.
• If the stock continues to price in much of the average Street target before broader proof emerges, the risk-reward becomes less attractive.